Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603060 | 1.00 | MAP3K14 (0.65) | MAP3K14ADRA2AKDM4CTAAR1HTR2C | |
| Hydrochloric Acid SCHEMBL31715418 | 0.98 | MAP3K14 (0.63) | MAP3K14ADRA2AKDM4CTAAR1HTR2C | |
| SCHEMBL27859985 | 0.86 | MAP3K14 (0.51) | MAP3K14ADRA2ATAAR1AHRMAOB | |
| SCHEMBL21436437 | 0.86 | MAP3K14 (0.51) | MAP3K14ADRA2ATAAR1AHRMAOB | |
| SCHEMBL1265783 | 0.86 | MAP3K14 (0.51) | MAP3K14ADRA2ATAAR1AHRMAOB | |
| Hydrochloric Acid SCHEMBL1066095 | 0.84 | MAP3K14 (0.50) | MAP3K14ADRA2ATAAR1HTR2CAHR | |
| Hydrochloric Acid SCHEMBL30563619 | 0.84 | MAP3K14 (0.50) | MAP3K14ADRA2ATAAR1HTR2CAHR | |
| Hydrochloric Acid SCHEMBL26962503 | 0.84 | MAP3K14 (0.50) | MAP3K14ADRA2ATAAR1HTR2CAHR | |
| Hydrochloric Acid SCHEMBL1066097 | 0.84 | MAP3K14 (0.50) | MAP3K14ADRA2ATAAR1HTR2CAHR | |
| SCHEMBL20554628 | 0.83 | PTGDR2 (0.47) | MAP3K14KDM4CMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12365670-B2 | GLP-IR agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2025-07-22 | — | — | US | disclosed |
| CN-113227068-B | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| WO-2021217508-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2α AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-11-04 | — | — | WO | disclosed |
| EP-3883928-A1 | GLP-1R AGONISTS AND USES THEREOF | Qilu Regor Therapeutics Inc. (CN) | 2021-09-29 | — | — | EP | disclosed |
| CN-113227068-A | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-10844049-B2 | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-10844049-B2 | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-09-10 | — | — | US | disclosed |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-09-10 | — | — | US | disclosed |
| US-7662811-B2 | N-(((5R)-5-((1-methylethyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl)methyl)-2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-pyrazinyl)acetamide; for treatment of pain and diseases, such as inflammation mediated diseases | AMGEN INC. (US) | 2010-02-16 | — | — | US | disclosed |
| EP-1817294-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | Amgen Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006019975-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | AMGEN INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AMGEN INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, IAPP | MAP3K14 1227/4885ADRA2A 874/4885KDM4C 3015/4885 |
| US-10844049-B2 | GLP-1R agonists and uses thereof | GLP1R, GPR119, GIPR | MAP3K14 1892/4885ADRA2A 119/4885KDM4C 3348/4885 |
| US-12365670-B2 | GLP-IR agonists and uses thereof | GLP1R, GPR119, GIPR | MAP3K14 1993/4885ADRA2A 103/4885KDM4C 4408/4885 |
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AADAC, PTGES2, LTC4S | MAP3K14 1410/4885ADRA2A 880/4885KDM4C 987/4885 |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | MAP3K14 1892/4885ADRA2A 119/4885KDM4C 3348/4885 |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | MAP3K14 2100/4885ADRA2A 121/4885KDM4C 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.